Sign in
PTHS Stock Price, Chart, Stats & News
Pelthos Therapeutics Inc.
Save
Pelthos Therapeutics Inc. (PTHS) does not currently pay a dividend.
–
Market cap
–
Current P/E
–
Forward P/E
PTHS chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 62.65% |
Operating margin | -193.09% |
Pretax margin | -301.91% |
Net margin | -257.93% |
Effective tax rate | 14.57% |
ROA | -33.22% |
ROE | -200.45% |
D/E | 0.90x |
Interest coverage ratio | -10.77x |
PTHS valuation
P/E | – |
P/S | 0.84x |
P/B | 1.77x |
P/CF | -3.05x |
P/FCF | -0.62x |
P/OCF | -3.05x |
PEG | 0.16x |
EV multiple | 0.09x |
About
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research.
Similar securities
Based on sector and market capitalization
Report issue